
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6154791/publications.pdf Version: 2024-02-01



ΔΝΝΑ ΣΟΓΙΝΙ

#	Article	IF	CITATIONS
1	MG53 marks poor beta cell performance and predicts onset of type 2 diabetes in subjects with different degrees of glucose tolerance Diabetes and Metabolism, 2022, 48, 101292.	2.9	4
2	Challenges and opportunities in realâ€world evidence on the renal effects of sodiumâ€glucose cotransporterâ€2 inhibitors. Diabetes, Obesity and Metabolism, 2022, 24, 177-186.	4.4	11
3	Molecular Characterization of Peritoneal Involvement in Primary Colon and Ovary Neoplasm: The Possible Clinical Meaning of the P2X7 Receptor-Inflammasome Complex. European Surgical Research, 2022, 63, 114-122.	1.3	5
4	The IGFBP3/TMEM219 pathway regulates beta cell homeostasis. Nature Communications, 2022, 13, 684.	12.8	16
5	P2X7 Receptor and Heart Function in a Mouse Model of Systemic Inflammation Due to High Fat Diet. Journal of Inflammation Research, 2022, Volume 15, 2425-2439.	3.5	8
6	The P2X7R-NLRP3 and AIM2 Inflammasome Platforms Mark the Complexity/Severity of Viral or Metabolic Liver Damage. International Journal of Molecular Sciences, 2022, 23, 7447.	4.1	5
7	Differential metabolomic signatures of declining renal function in Types 1 and 2 diabetes. Nephrology Dialysis Transplantation, 2021, 36, 1859-1866.	0.7	4
8	SGLT2 inhibitors and thiazide enhance excretion of DEHP toxic metabolites in subjects with type 2 diabetes: A randomized clinical trial. Environmental Research, 2021, 192, 110316.	7.5	9
9	Short-term impact of COVID-19 lockdown on metabolic control of patients with well-controlled type 2 diabetes: a single-centre observational study. Acta Diabetologica, 2021, 58, 431-436.	2.5	47
10	Effect of Treatment of Periodontitis on Incretin Axis in Obese and Nonobese Individuals: A Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e74-e82.	3.6	7
11	Independent association of atherogenic dyslipidaemia with allâ€cause mortality in individuals with type 2 diabetes and modifying effect of gender: a prospective cohort study. Cardiovascular Diabetology, 2021, 20, 28.	6.8	6
12	Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance. Function, 2021, 2, zqab005.	2.3	29
13	Normal Versus Slowly Processed Pasta and Post-Prandial Glucose Homeostasis in Healthy Subjects: A Pilot Study. Nutrients, 2021, 13, 678.	4.1	0
14	Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?. Diabetes Care, 2021, 44, 647-654.	8.6	31
15	Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. BMC Medicine, 2021, 19, 66.	5.5	32
16	All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease. Acta Diabetologica, 2021, 58, 1425-1428.	2.5	0
17	miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy. American Journal of Transplantation, 2021, 21, 3280-3295.	4.7	14
18	Clinical and epigenetic determinants of edentulism in type 2 diabetic subjects referring to a tertiary center. Journal of Diabetes and Its Complications, 2021, 35, 107910.	2.3	2

#	Article	IF	CITATIONS
19	Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study. Clinical Interventions in Aging, 2021, Volume 16, 1037-1046.	2.9	10
20	P2X7 receptor/NLRP3 inflammasome complex and αâ€synuclein in peripheral blood mononuclear cells: a prospective study in neoâ€diagnosed, treatmentâ€naÃīve Parkinson's disease. European Journal of Neurology, 2021, 28, 2648-2656.	3.3	12
21	The P2X7 Receptor: A Promising Pharmacological Target in Diabetic Retinopathy. International Journal of Molecular Sciences, 2021, 22, 7110.	4.1	17
22	Physical activity as a proxy to ameliorate inflammation in patients with type 2 diabetes and periodontal disease at high cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2199-2209.	2.6	7
23	A long-term nationwide study on chronic kidney disease-related mortality in Italy: trends and associated comorbidity. Journal of Nephrology, 2021, , 1.	2.0	4
24	Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. Pharmaceuticals, 2021, 14, 995.	3.8	9
25	Protein and amino acids in nonalcoholic fatty liver disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2021, 24, 96-101.	2.5	42
26	Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice. Advances in Chronic Kidney Disease, 2021, 28, 328-336.	1.4	5
27	Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. BMJ Open Diabetes Research and Care, 2020, 8, e001481.	2.8	22
28	Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovascular Diabetology, 2020, 19, 196.	6.8	52
29	Phenotyping individuals with newly-diagnosed type 2 diabetes at risk for all-cause mortality: a single centre observational, prospective study. Diabetology and Metabolic Syndrome, 2020, 12, 47.	2.7	2
30	miR-130a and Tgfβ Content in Extracellular Vesicles Derived from the Serum of Subjects at High Cardiovascular Risk Predicts their In-Vivo Angiogenic Potential. Scientific Reports, 2020, 10, 706.	3.3	13
31	Association between On-Treatment Haemoglobin A1c and All-Cause Mortality in Individuals with Type 2 Diabetes: Importance of Personalized Goals and Type of Anti-Hyperglycaemic Treatment. Journal of Clinical Medicine, 2020, 9, 246.	2.4	2
32	Cardiovascular protection with sodiumâ€glucose coâ€transporterâ€2 inhibitors in type 2 diabetes: Does it apply to all patients?. Diabetes, Obesity and Metabolism, 2020, 22, 1481-1495.	4.4	17
33	Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovascular Diabetology, 2020, 19, 46.	6.8	43
34	Diabetes and the Kidney. Endocrinology, 2020, , 203-230.	0.1	0
35	Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes, Obesity and Metabolism, 2019, 21, 252-260.	4.4	33
36	The Effects of Dapagliflozin on Systemic and Renal Vascular Function Display an Epigenetic Signature. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4253-4263.	3.6	57

#	Article	IF	CITATIONS
37	Similar effectiveness of dapagliflozin and GLPâ€1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. Diabetes, Obesity and Metabolism, 2019, 21, 1886-1894.	4.4	17
38	ls resistant hypertension an independent predictor of all-cause mortality in individuals with type 2 diabetes? A prospective cohort study. BMC Medicine, 2019, 17, 83.	5.5	9
39	Phthalates Exposure as Determinant of Albuminuria in Subjects With Type 2 Diabetes: A Cross-Sectional Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1491-1499.	3.6	16
40	Role of the P2X7 receptor in the pathogenesis of type 2 diabetes and its microvascular complications. Current Opinion in Pharmacology, 2019, 47, 75-81.	3.5	35
41	Pharmacological blockade of the P2X7 receptor reverses retinal damage in a rat model of type 1 diabetes. Acta Diabetologica, 2019, 56, 1031-1036.	2.5	30
42	Alterations in Carotid Parameters in ApoE–/– Mice Treated with a High-Fat Diet: A Micro-ultrasound Analysis. Ultrasound in Medicine and Biology, 2019, 45, 980-988.	1.5	2
43	Periodontitis affects glucoregulatory hormones in severely obese individuals. International Journal of Obesity, 2019, 43, 1125-1129.	3.4	12
44	Renal Resistive Index Predicts Post–Bariatric Surgery Renal Outcome in Nondiabetic Individuals with Severe Obesity. Obesity, 2019, 27, 68-74.	3.0	10
45	DNA methylation of genes regulating appetite and prediction of weight loss after bariatric surgery in obese individuals. Journal of Endocrinological Investigation, 2019, 42, 37-44.	3.3	6
46	Diabetes and the Kidney. Endocrinology, 2019, , 1-28.	0.1	0
47	P2X receptor-ion channels in the inflammatory response in adipose tissue and pancreas — potential triggers in onset of type 2 diabetes?. Current Opinion in Immunology, 2018, 52, 1-7.	5.5	30
48	Haemoglobin A1c variability is a strong, independent predictor of allâ€cause mortality in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1885-1893.	4.4	45
49	PDGF-BB Carried by Endothelial Cell–Derived Extracellular Vesicles Reduces Vascular Smooth Muscle Cell Apoptosis in Diabetes. Diabetes, 2018, 67, 704-716.	0.6	38
50	The level of physical training modulates cytokine levels through P2X7 receptor in healthy subjects. European Journal of Clinical Investigation, 2018, 48, e12880.	3.4	13
51	A systematic review and metaâ€analysis of epidemiologic observational evidence on the effect of periodontitis on diabetes An update of the <scp>EFP</scp> â€ <scp>AAP</scp> review. Journal of Clinical Periodontology, 2018, 45, 167-187.	4.9	245
52	Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Acta Diabetologica, 2018, 55, 603-612.	2.5	33
53	Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. Frontiers in Endocrinology, 2018, 9, 649.	3.5	65
54	Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study. Acta Diabetologica, 2018, 55, 1121-1129.	2.5	2

#	Article	IF	CITATIONS
55	Ultrasonographic Characterization of the <i>db/db</i> Mouse: An Animal Model of Metabolic Abnormalities. Journal of Diabetes Research, 2018, 2018, 1-9.	2.3	12
56	Islet-Derived eATP Fuels Autoreactive CD8+ T Cells and Facilitates the Onset of Type 1 Diabetes. Diabetes, 2018, 67, 2038-2053.	0.6	17
57	Diabetes and the Kidney. Endocrinology, 2018, , 1-27.	0.1	0
58	Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study. Diabetologia, 2018, 61, 2277-2289.	6.3	83
59	A renal genetic risk score (GRS) is associated with kidney dysfunction in people with type 2 diabetes. Diabetes Research and Clinical Practice, 2018, 144, 137-143.	2.8	5
60	Diabetes and the Kidney. Endocrinology, 2018, , 203-229.	0.1	0
61	Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT 2A receptor agonism. European Neuropsychopharmacology, 2017, 27, 383-398.	0.7	44
62	Sodiumâ€glucose coâ€ŧransporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1289-1294.	4.4	66
63	Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes and Metabolism, 2017, 43, 512-520.	2.9	51
64	The P2X7 receptor– <scp>NLRP</scp> 3 inflammasome complex predicts the development of nonâ€Hodgkin's lymphoma in Sjogren's syndrome: a prospective, observational, singleâ€centre study. Journal of Internal Medicine, 2017, 282, 175-186.	6.0	49
65	Determinants of glomerular filtration rate following bariatric surgery in individuals with severe, otherwise uncomplicated, obesity: an observational, prospective study. Acta Diabetologica, 2017, 54, 593-598.	2.5	7
66	Silent coronary heart disease in patients with type 2 diabetes: application of a screening approach in a follow-up study. Journal of Diabetes and Its Complications, 2017, 31, 952-957.	2.3	5
67	SGLT inhibition in T1DM — definite benefit with manageable risk. Nature Reviews Endocrinology, 2017, 13, 698-699.	9.6	6
68	Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes). Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1089-1097.	2.6	26
69	Heterozygosity for the rs696217 SNP in the Preproghrelin Gene Predicts Weight Loss After Bariatric Surgery in Severely Obese Individuals. Obesity Surgery, 2017, 27, 961-967.	2.1	18
70	Deficiency of the Purinergic Receptor 2X ₇ Attenuates Nonalcoholic Steatohepatitis Induced by High-Fat Diet: Possible Role of the NLRP3 Inflammasome. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14.	4.0	23
71	Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovascular Diabetology, 2017, 16, 138.	6.8	274
72	P2X7 Receptor and APOE Polymorphisms and Survival from Heart Failure: A Prospective Study in Frail		6

Patients in a Geriatric Unit. , 2017, 8, 434.

#	Article	IF	CITATIONS
73	The EMPA-REG outcome study: critical appraisal and potential clinical implications. Cardiovascular Diabetology, 2016, 15, 85.	6.8	16
74	Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Acta Diabetologica, 2016, 53, 863-870.	2.5	18
75	Syphilis iridocyclitis in a patient with type 1 diabetes. Journal of Diabetes Investigation, 2016, 7, 641-644.	2.4	2
76	What Should Be the Target Blood Pressure in Elderly Patients With Diabetes?. Diabetes Care, 2016, 39, S234-S243.	8.6	21
77	Metabolic and Hormonal Determinants of Glomerular Filtration Rate and Renal Hemodynamics in Severely Obese Individuals. Obesity Facts, 2016, 9, 310-320.	3.4	15
78	[OP.7B.10] EFFECT OF BARIATRIC SURGERY ON VASCULAR AND RENAL BIOMARKERS IN MORBIDLY OBESE, NORMOTENSIVE, NON-DIABETIC PATIENTS. Journal of Hypertension, 2016, 34, e88-e89.	0.5	2
79	Extraâ€glycaemic properties of empagliflozin. Diabetes/Metabolism Research and Reviews, 2016, 32, 230-237.	4.0	7
80	Prediction of Declining Renal Function and Albuminuria in Patients With Type 2 Diabetes by Metabolomics. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 696-704.	3.6	62
81	Saxagliptin prevents vascular remodeling and oxidative stress in db/db mice. Role of endothelial nitric oxide synthase uncoupling and cyclooxygenase. Vascular Pharmacology, 2016, 76, 62-71.	2.1	25
82	Obesity reduces the pro-angiogenic potential of adipose tissue stem cell-derived extracellular vesicles (EVs) by impairing miR-126 content: impact on clinical applications. International Journal of Obesity, 2016, 40, 102-111.	3.4	95
83	Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. Arthritis Research and Therapy, 2015, 17, 277.	3.5	55
84	Predictive value of dynamic renal resistive index (drin) for renal outcome in type 2 diabetes and essential hypertension: a prospective study. Cardiovascular Diabetology, 2015, 14, 63.	6.8	22
85	Tumour necrosis factor-alpha participates on the endothelin-1/nitric oxide imbalance in small arteries from obese patients: role of perivascular adipose tissue. European Heart Journal, 2015, 36, 784-794.	2.2	127
86	Hormone replacement therapy, renal function and heart ultrasonographic parameters in postmenopausal women: an observational study. International Journal of Clinical Practice, 2015, 69, 632-637.	1.7	7
87	Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Acta Diabetologica, 2015, 52, 971-981.	2.5	8
88	The Dark Side of Extracellular ATP in Kidney Diseases. Journal of the American Society of Nephrology: JASN, 2015, 26, 1007-1016.	6.1	72
89	Acute effects of different degrees of ultraâ€endurance exercise on systemic inflammatory responses. Internal Medicine Journal, 2015, 45, 74-79.	0.8	41
90	Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. PLoS ONE, 2015, 10, e0125512.	2.5	30

#	Article	IF	CITATIONS
91	Genetic interaction of <i>P2X7</i> receptor and <i>VEGFR-2</i> polymorphisms identifies a favorable prognostic profile in prostate cancer patients. Oncotarget, 2015, 6, 28743-28754.	1.8	21
92	The complex <scp>P</scp> 2 <scp>X</scp> ₇ receptor/inflammasome in perivascular fat tissue of heavy smokers. European Journal of Clinical Investigation, 2014, 44, 295-302.	3.4	32
93	Role of Podocyte B7-1 in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2014, 25, 1415-1429.	6.1	114
94	Resistant hypertension in patients with type 2 diabetes. Journal of Hypertension, 2014, 32, 2401-2410.	0.5	35
95	Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovascular Diabetology, 2014, 13, 59.	6.8	24
96	The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 577-584.	2.6	4
97	Blood pressure variability: A new target to slow the progression of vascular damage in type 2 diabetes?. Journal of Diabetes and Its Complications, 2014, 28, 117-118.	2.3	1
98	Chronic kidney disease in type 2 diabetes: Lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 815-822.	2.6	51
99	Impact of mild to moderate reductions of glomerular filtration rate on coronary artery disease severity. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 681-688.	2.6	18
100	Comparison of Agents That Affect Aldosterone Action. Seminars in Nephrology, 2014, 34, 285-306.	1.6	28
101	HbA1c Variability as an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 2301-2310.	8.6	130
102	Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the <scp>RIACE</scp> Italian multicentre study. Journal of Internal Medicine, 2013, 274, 176-191.	6.0	111
103	Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study. Cardiovascular Diabetology, 2013, 12, 98.	6.8	61
104	Adipocytokines mark insulin sensitivity in euthyroid Hashimoto's patients. Acta Diabetologica, 2013, 50, 73-80.	2.5	4
105	How can resistant hypertension be identified and prevented?. Nature Reviews Cardiology, 2013, 10, 293-296.	13.7	9
106	P2X7 receptor polymorphisms do not influence endothelial function and vascular tone in neo-diagnosed, treatment-naive essential hypertensive patients. Journal of Hypertension, 2013, 31, 2362-2369.	0.5	11
107	The purinergic 2X ₇ receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation. Journal of Pathology, 2013, 231, 342-353.	4.5	99
108	The P2X ₇ receptor–inflammasome complex has a role in modulating the inflammatory response in primary <scp>S</scp> jögren's syndrome. Journal of Internal Medicine, 2013, 274, 480-489.	6.0	74

#	Article	IF	CITATIONS
109	VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. British Journal of Cancer, 2013, 109, 957-964.	6.4	41
110	Age, Renal Dysfunction, Cardiovascular Disease, and Antihyperglycemic Treatment in Type 2 Diabetes Mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. Journal of the American Geriatrics Society, 2013, 61, 1253-1261.	2.6	65
111	THU0304â€Gross Cystic Disease Fluid Protein-15(GCDFP-15)/Prolactin-Inducible Protein (PIP): A Functional Salivary Biomarker for Primary SjöGren's Syndrome?. Annals of the Rheumatic Diseases, 2013, 72, A268.4-A269.	0.9	0
112	Diverging Association of Reduced Glomerular Filtration Rate and Albuminuria With Coronary and Noncoronary Events in Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 143-149.	8.6	107
113	Rate and Determinants of Association Between Advanced Retinopathy and Chronic Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 2317-2323.	8.6	106
114	Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition. European Heart Journal, 2012, 33, 2225-2234.	2.2	28
115	SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nature Reviews Endocrinology, 2012, 8, 495-502.	9.6	364
116	Adipocytokine levels mark endothelial function in normotensive individuals. Cardiovascular Diabetology, 2012, 11, 103.	6.8	25
117	High prevalence of advanced retinopathy in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Diabetes Research and Clinical Practice, 2012, 98, 329-337.	2.8	29
118	Combination Therapy in Hypertension. Current Cardiovascular Risk Reports, 2012, 6, 291-298.	2.0	1
119	The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation provides a better definition of cardiovascular burden associated with CKD than the Modification of Diet in Renal Disease (MDRD) Study formula in subjects with type 2 diabetes. Atherosclerosis, 2011, 218, 194-199.	0.8	55
120	Adipocyte P2X7 receptors expression: A role in modulating inflammatory response in subjects with metabolic syndrome?. Atherosclerosis, 2011, 219, 552-558.	0.8	43
121	Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. Journal of Hypertension, 2011, 29, 1802-1809.	0.5	198
122	Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation. Journal of Hypertension, 2011, 29, 1930-1939.	0.5	15
123	Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) study. Nephrology Dialysis Transplantation, 2011, 26, 3950-3954.	0.7	65
124	Pathophysiology, Prevention and Management of Chronic Kidney Disease in the Hypertensive Patient With Diabetes Mellitus. Journal of Clinical Hypertension, 2011, 13, 252-257.	2.0	12
125	Dynamic evaluation of renal resistive index in normoalbuminuric patients with newly diagnosed hypertension or type 2 diabetes. Diabetologia, 2011, 54, 2430-2439.	6.3	48
126	Effect of a fatty meal on inflammatory markers in healthy volunteers with a family history of type 2 diabetes. British Journal of Nutrition, 2011, 106, 364-368.	2.3	18

#	Article	IF	CITATIONS
127	RAS Blockade for Every Diabetic Patient: Pro and Con. Diabetes Care, 2011, 34, S320-S324.	8.6	10
128	Pattern of expression of inflammatory markers in adipose tissue of untreated hypertensive patients. Journal of Hypertension, 2010, 28, 1459-1465.	0.5	16
129	Hypothyroidism and Intermediate Metabolism: A Complex Relationship. Thyroid, 2010, 20, 837-839.	4.5	7
130	Soluble Human Leukocyte Antigen-G Expression and Glucose Tolerance in Subjects with Different Degrees of Adiposity. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3342-3346.	3.6	25
131	Retinol-Binding Protein-4 in Women With Untreated Essential Hypertension. American Journal of Hypertension, 2009, 22, 1001-1006.	2.0	61
132	Soluble CD40 Ligand Levels in Essential Hypertensive Men: Evidence of a Possible Role of Insulin Resistance. American Journal of Hypertension, 2009, 22, 1007-1013.	2.0	14
133	Extracellular Adenosine 5′-Triphosphate Modulates Insulin Secretion via Functionally Active Purinergic Receptors of X and Y Subtype. Endocrinology, 2009, 150, 2596-2602.	2.8	17
134	Short-term Acute Hyperinsulinemia and Prothrombotic Factors in Subjects with Normal Glucose Tolerance. Hormone and Metabolic Research, 2009, 41, 568-572.	1.5	2
135	1513A>C Polymorphism in the P2X7 Receptor Gene in Patients with Papillary Thyroid Cancer: Correlation with Histological Variants and Clinical Parameters. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 695-698.	3.6	43
136	Family history of hypertension, anthropometric parameters and markers of early atherosclerosis in young healthy individuals. Journal of Human Hypertension, 2009, 23, 801-807.	2.2	17
137	TIMP3 Is Reduced in Atherosclerotic Plaques From Subjects With Type 2 Diabetes and Increased by SirT1. Diabetes, 2009, 58, 2396-2401.	0.6	132
138	Effects of different LDL particles on inflammatory molecules in human mesangial cells. Diabetologia, 2008, 51, 2117-2125.	6.3	35
139	Rosiglitazone increases matrix production and quenches inflammation: studies in human cells. Diabetes/Metabolism Research and Reviews, 2008, 24, 197-204.	4.0	4
140	Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 624-631.	2.6	67
141	Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. Journal of Endocrinological Investigation, 2008, 31, 660-665.	3.3	18
142	Increased P2X7 Receptor Expression and Function in Thyroid Papillary Cancer: A New Potential Marker of the Disease?. Endocrinology, 2008, 149, 389-396.	2.8	123
143	Multiple P2X receptors are involved in the modulation of apoptosis in human mesangial cells: evidence for a role of P2X4. American Journal of Physiology - Renal Physiology, 2007, 292, F1537-F1547.	2.7	30
144	Effects of endothelin-1 on fibroblasts from type 2 diabetic patients: Possible role in wound healing and tissue repair. Growth Factors, 2007, 25, 392-399.	1.7	13

#	Article	IF	CITATIONS
145	Increased sensitivity to extracellular ATP of fibroblasts from patients affected by systemic sclerosis. Annals of the Rheumatic Diseases, 2007, 66, 1124-1125.	0.9	9
146	Correspondence Between the International Diabetes Federation Criteria for Metabolic Syndrome and Insulin Resistance in a Cohort of Italian Nondiabetic Caucasians: The GISIR database. Diabetes Care, 2007, 30, e33-e33.	8.6	4
147	Acute retinal ganglion cell injury caused by intraocular pressure spikes is mediated by endogenous extracellular ATP. European Journal of Neuroscience, 2007, 25, 2741-2754.	2.6	128
148	High glucose and homocysteine synergistically affect the metalloproteinases–tissue inhibitors of metalloproteinases pattern, but not TGFB expression, in human fibroblasts. Diabetologia, 2006, 49, 2499-2506.	6.3	26
149	Acute Vascular Events and Electrolytes Variations in Elderly Patients. Hormone and Metabolic Research, 2006, 38, 197-202.	1.5	13
150	Effect of short-term folic acid supplementation on insulin sensitivity and inflammatory markers in overweight subjects. International Journal of Obesity, 2006, 30, 1197-1202.	3.4	105
151	Enhanced angiotensin II-mediated effects in fibroblasts of patients with familial hypercholesterolemia. Journal of Hypertension, 2005, 23, 367-374.	0.5	10
152	Purinergic modulation of mesangial extracellular matrix production: Role in diabetic and other glomerular diseases. Kidney International, 2005, 67, 875-885.	5.2	63
153	Selective Insulin Resistance Affecting Nitric Oxide Release But Not Plasminogen Activator Inhibitor-1 Synthesis in Fibroblasts From Insulin-Resistant Individuals. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2392-2397.	2.4	18
154	Antihypertensive Treatment and Multifactorial Approach for Renal Protection in Diabetes. Journal of the American Society of Nephrology: JASN, 2005, 16, S18-S21.	6.1	27
155	Extracellular Adenosine 5′-Triphosphate Modulates Interleukin-6 Production by Human Thyrocytes through Functional Purinergic P2 Receptors. Endocrinology, 2005, 146, 3172-3178.	2.8	21
156	Enhanced P2X 7 Activity in Human Fibroblasts From Diabetic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1240-1245.	2.4	50
157	Lipoprotein lipase gene variants and progression of nephropathy in hypercholesterolaemic patients with type 2 diabetes. Journal of Internal Medicine, 2004, 256, 30-36.	6.0	11
158	Defective P2Y purinergic receptor function: A possible novel mechanism for impaired glucose transport. Journal of Cellular Physiology, 2003, 197, 435-444.	4.1	26
159	Effect of metabolic control on homocysteine levels in type 2 diabetic patients: a 3-year follow-up. Journal of Internal Medicine, 2003, 254, 264-271.	6.0	23
160	Atorvastatin improves metabolic control and endothelial function in Type 2 diabetic patients: A placebo-controlled study. Journal of Endocrinological Investigation, 2003, 26, 73-78.	3.3	44
161	PC-1 Amino Acid Variant Q121 Is Associated With a Lower Clomerular Filtration Rate in Type 2 Diabetic Patients With Abnormal Albumin Excretion Rates. Diabetes Care, 2003, 26, 2898-2902.	8.6	17
162	Metabolic Profile in Patients with Benign Prostate Hyperplasia or Prostate Cancer and Normal Glucose Tolerance. Hormone and Metabolic Research, 2003, 35, 296-300.	1.5	13

#	Article	IF	CITATIONS
163	The Angiotensin-Converting Enzyme DD Genotype Is Associated With Glomerulopathy Lesions in Type 2 Diabetes. Diabetes, 2002, 51, 251-255.	0.6	43
164	P2 receptors: new potential players in atherosclerosis. British Journal of Pharmacology, 2002, 135, 831-842.	5.4	113
165	Plasma homocysteine, methylenetetrahydrofolate reductase mutation and carotid damage in elderly healthy women. Atherosclerosis, 2001, 157, 175-180.	0.8	41
166	Role of diabetes in influencing leptin concentration in elderly overweight patients. European Journal of Endocrinology, 2001, 145, 173-179.	3.7	8
167	ACE Genotype and Endothelium-Dependent Vasodilation of Conduit Arteries and Forearm Microcirculation in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1313-1319.	2.4	20
168	A Defect in Glycogen Synthesis Characterizes Insulin Resistance in Hypertensive Patients With Type 2 Diabetes. Hypertension, 2001, 37, 1492-1496.	2.7	15
169	Factors influencing plasma homocysteine levels in type 2 diabetes. Diabetes Care, 2000, 23, 420-421.	8.6	17
170	High glucose modulates P2X 7 receptor-mediated function in human primary fibroblasts. Diabetologia, 2000, 43, 1248-1256.	6.3	51
171	The relationship of plasma glucose and electrocardiographic parameters in elderly women with different degrees of glucose tolerance. Aging Clinical and Experimental Research, 2000, 12, 249-255.	2.9	8
172	Polymorphisms of angiotensin-converting enzyme and angiotensinogen genes in type 2 diabetic sibships in relation to albumin excretion rate. American Journal of Kidney Diseases, 1999, 34, 1002-1009.	1.9	24
173	Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. Journal of Cell Science, 1999, 112, 297-305.	2.0	134
174	Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. Journal of Cell Science, 1999, 112 (Pt 3), 297-305.	2.0	52
175	Elevated PC-1 content in cultured skin fibroblasts correlates with decreased in vivo and in vitro insulin action in nondiabetic subjects: evidence that PC-1 may be an intrinsic factor in impaired insulin receptor signaling. Diabetes, 1998, 47, 1095-1100.	0.6	66
176	Derangements in Protein Metabolism Induced by Type I Diabetes mellitus. Mineral and Electrolyte Metabolism, 1998, 24, 41-46.	1.1	6
177	Protein Metabolism in Human Obesity: Relationship with Glucose and Lipid Metabolism and with Visceral Adipose Tissue ¹ . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2552-2558.	3.6	46
178	Glycosaminoglycans Delay the Progression of Nephropathy in NIDDM. Diabetes Care, 1997, 20, 819-823.	8.6	74
179	and countertransport activity in hypertensive non—inusulin-dependent diabetic patients: Role in insulin resistance and antihypertensive treatment. Metabolism: Clinical and Experimental, 1997, 46, 1316-1323.	3.4	20
180	Protein Metabolism in Human Obesity: Relationship with Glucose and Lipid Metabolism and with Visceral Adipose Tissue. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2552-2558.	3.6	43

#	Article	IF	CITATIONS
181	Intracellular calcium handling by fibroblasts from non-insulin dependent diabetic patients with and without hypertension and microalbuminuria. Kidney International, 1996, 50, 618-626.	5.2	6
182	Hypertension, Cardiovascular Disease, Diabetes Mellitus, and Diabetic Nephropathy: Role of Insulin Resistance. , 1996, , 61-74.		2
183	Insulin Sensitivity Is Not Impaired In Mexican-American Women Without a Family History Of Diabetes. Diabetes Care, 1995, 18, 825-833.	8.6	8
184	Lipoprotein abnormalities in non-insulin-dependent diabetic patients with impaired extrahepatic insulin sensitivity, hypertension, and microalbuminuria Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 911-916.	3.9	16
185	Impaired Insulin-Induced Glucose Uptake by Extrahepatic Tissue Is Hallmark of NIDDM Patients Who Have or Will Develop Hypertension and Microalbuminuria. Diabetes, 1994, 43, 491-499.	0.6	62
186	Peripheral, rather than hepatic, insulin resistance and atherogenic lipoprotein phenotype predict cardiovascular complications in NIDDM. European Journal of Clinical Investigation, 1994, 24, 258-266.	3.4	21
187	Impaired insulin-induced glucose uptake by extrahepatic tissue is hallmark of NIDDM patients who have or will develop hypertension and microalbuminuria. Diabetes, 1994, 43, 491-499.	0.6	27
188	Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes. Kidney International, 1993, 44, 139-146.	5.2	58
189	In vivo Glucose Metabolism in Obese and Type II Diabetic Subjects With or Without Hypertension. Diabetes, 1993, 42, 764-772.	0.6	37
190	Effects of physiological hyperinsulinemia on the intracellular metabolic partition of plasma glucose. American Journal of Physiology - Endocrinology and Metabolism, 1993, 265, E943-E953.	3.5	11
191	Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus Journal of Clinical Investigation, 1993, 91, 484-494.	8.2	152
192	In vivo glucose metabolism in obese and type II diabetic subjects with or without hypertension. Diabetes, 1993, 42, 764-772.	0.6	8
193	Total Body Fat Content and Fat Topography Are Associated Differently With In Vivo Glucose Metabolism in Nonobese and Obese Nondiabetic Women. Diabetes, 1992, 41, 1151-1159.	0.6	145
194	Lower limb arterio-venous shunts, autonomic neuropathy and diabetic foot. Diabetes Research and Clinical Practice, 1992, 16, 123-130.	2.8	52
195	Glucose and amino acid metabolism in chronic renal failure: effect of insulin and amino acids. American Journal of Physiology - Renal Physiology, 1992, 262, F168-F176.	2.7	32
196	Poor metabolic control and predisposition to hypertension, rather than hypertension itself, are risk factors for nephropathy in type 2 diabetes. Acta Diabetologica, 1992, 29, 123-129.	2.5	7
197	Insulin resistance, hypertension and cellular ion transport systems. Acta Diabetologica, 1992, 29, 196-200.	2.5	5
198	Close relationship between microalbuminuria and insulin resistance in essential hypertension and non-insulin dependent diabetes mellitus Journal of the American Society of Nephrology: JASN, 1992, 3, S56.	6.1	47

#	Article	IF	CITATIONS
199	Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. Diabetes, 1992, 41, 1151-1159.	0.6	33
200	Somatostatin response to a mixed meal in normals and in type I diabetics. Peptides, 1986, 7, 287-291.	2.4	5
201	Somatostatin plasma levels and biological effects following subcutaneous administration of somatostatin in man. European Journal of Endocrinology, 1986, 113, 465-470.	3.7	1